Skip to main content

Table 1 Laboratory parameters before institution of atorvastatin treatment (visit 1) and after 3 months (visit 2)

From: Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment

  HS (n = 17) Pts (n = 30)
   P* vs Pts    P**
   Visit 1 Visit 2 Visit 1 Visit 2 Visit 2 vs 1
Tot-c (mg/dL) 198.0 (188.5–221.5) <0.0001 0.036 269.0 (226.0–318.0) 166.0 (141.5–204.5) <0.0001
LDL-c (mg/dL) 115.0 (107.0–147.5) 0.003 n.s. 168.0 (119.3–263.5) 135.0 (94.0–196.5) 0.0013
HDL-c (mg/dL) 53.0 (44.0–67.5) n.s. n.s. 49.5 (42.8–56.3) 47.0 (39.5–54.5) n.s.
TG (mg/dL) 132.0 (102.5–163.5) 0.002 0.0004 181.5 (137.7–220.6) 87.0 (61.2–111.9) <0.0001
ApoA (mg/dL) 144.0 (121.5–161.0) n.s. n.s. 126.0 (114.3–139.5) 130.0 (112.0–143.5) n.s.
ApoB (mg/dL) 98.0 (85.0–108.5) <0.0001 0.038 139.0 (120.0–155.0) 80.0 (64.0–.98.0) <0.0001
hs-CRP (mg/L) 1.50 (0.60–2.70) n.s. n.s. 0.90 (0.45–2.20) 1.1 (0.7–2.4) n.s.
Glucose (mg/dL) 96 (89–97) n.s. n.s. 93.5 (89.75–102) 96 (89.75–100) n.s.
  1. Values are expressed as median and 25–75th percentile
  2. n.s. not significant
  3. * = Mann Whitney test; ** = Wilcoxon signed rank test